Skip to main content
Figure 1 | BMC Endocrine Disorders

Figure 1

From: Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFκB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus

Figure 1

Concentrations of plasma inflammation markers in controls and in diabetics before and after rosiglitazone treatment. Baseline concentrations of plasma inflammatory markers, A) hsCRP, B) TNFα, C) IL6 and D) MCP1, in type 2 diabetic and control subjects and levels after rosiglitazone treatment in type 2 diabetic patients. * = p-value < 0.05.

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us